昌吉平价人流费用昌吉男性龟头流脓是什么病,流产手术哪家医院好昌吉,昌吉包皮费用得多少,昌吉割包茎得多少费用,昌吉节育环怎么取出,昌吉医院精液检查要多少精液,昌吉做无痛打胎医院哪家好

The endless hum of the hive calls to Chuck Pressler. Each day, he visits the thousands of bees living in his backyard. It’s an appointment he hasn’t missed in years.“It slows you down,” said Pressler.The Navy veteran served four years during the Cold War. Pressler worked in a submarine unit, and now, he works as an EMT. He’s been called to help others in both his careers, but both have come with a price.“It is a sacrifice,” said Pressler. “Whether it's coming back from war, or whether it's dealing with things at home: police, paramedics, firemen, EMT, dispatchers. There is a lot of things that weigh on people after dealing with this for so long. There are humans behind these shields in uniform.”But Pressler found a unique way to take his mind away from the stress: tending several beehives in his backyard and harvesting the honey they produce.“You find yourself talking to them a little bit, and you forget about everything around you while you're doing it, and you're just paying attention to the bees,” said Pressler.He knew the calm he found had to be shared. “From my own experience of how I enjoy it, I discovered that it could be a tool, an actual tool for those that have either experienced PTSD, or just something to take them from their past experiences or their current everyday job.”Pressler started the non-profit Honeybees for Heroes to give other veterans and first responders a chance to ease the traumas they live with every day.“You know it's a brotherhood, sisterhood. It’s all a big family in the end, and everybody sticks together, and I think being around each other and talking, even in general, and dealing with honeybees is, is working towards getting past it,” said Pressler.For so many veterans, talking about mental health and PTSD can be a tough thing to do. That’s why coming out here and focusing on the honeybees can be so healing.“Generally, we don't talk about it unless they bring it up. I try not to revisit any ghosts or bring up any memories. The object is just to let them find their pace.”Pressler now works with a handful of veterans in his own neighborhood one-on-one, even setting them up with their own hives.He says many veterans feel misunderstood and alone, and he wants to be there to help.“Let's be honest, there is a stigma behind it, and people start to look at you like, you know, you're crazy. It's important for the community to know, on a bigger broad scale, that it's OK to deal with these issues and that the people that do these jobs are human and that it requires a human to make these sacrifices to do it,” said Pressler.Pressler said the call to serve is worth every sacrifice, and it’s a mission that doesn’t end when you leave the military.“All of us first responders, veterans all that, that's what we do. We help protect people,” he said.He hopes more will soon realize: fulfilling that promise can come from the most unexpected places.“When you have a beehive with 60,000 honeybees in it, you're their guardian,” said Pressler. “I always say I'm the keeper of the bees or the protector of the bees, but we are their guardian. It’s up to us to protect them and serve them.”If you'd like to help, you can donate to Honeybees for Heroes HERE. 3223

The family of a Pennsylvania woman who died in jail in 2015 from heroin withdrawal symptoms was awarded .75 million in a wrongful death suit settlement this week, CBS News reported. Victoria "Tori" Herr, then 18, died on April 5, 2015, nine days after being arrested after police found drugs in the woman's apartment. Herr told police that she had consumed 10 bags of heroin a day. During her first four days in custody, Herr reportedly suffered from bouts of vomiting and diarrhea. She was treated with water and Ensure, but was unable to keep her fluids down. The result of those symptoms led her to cardiac arrest and to lose consciousness, CBS News reported. Herr's lawyers claimed that the Lebanon County Correctional Facility did not meet her basic medical needs, and then lied. "Anyone who looked at her would have known that she was very sick and that she needed attention," Herr's family lawyer Jonathan Feinberg told CBS. "There was a complete disregard for her needs, which can only be tied back to the fact that she was addicted to drugs."As part of the multi-million-dollar settlement, the jail's warden, nurses and other employees agree that there was no wrongdoing. To read CBS News' full report, click here.  1284

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The Democratic National Convention gets underway this week. Republicans will hold their convention next week. While this year's convention is virtual for both parties, have you asked yourself what's the point of these anyway?CONVENTIONS YEARS AGO WERE DIFFERENT Americans have known for months that Joe Biden is going to be the Democratic nominee and that Donald Trump would be the Republican nominee. However, before political parties started relying on primaries, conventions were the place the nominee was decided.In 1856, it took Abraham Lincoln three rounds of voting to become the Republican nominee. In 1924, Democrats needed 103 ballots over 16 days to pick John Davis as their party nominee.CONVENTIONS PURPOSE In 1948, networks began televising conventions and since then, many argue conventions have become taxpayer-funded spectacles for insiders. While taxpayers are no longer directly funding conventions, they are paying for security. In 2016, it was estimated that around 0 million of taxpayer funds were spent on convention security. 1952 was the last year both political parties had a contested convention; however, party insiders believe conventions still play a pivotal role. Conventions are where networking can take place and where delegates can debate the party platform. It's also a place where training sessions can occur and speeches can take place. Could Barack Obama have become president in 2008 without his speech at the 2004 convention? Sure, it's possible, but that speech was credited with making the Illinois state senator a household name. WILL 2020 CHANGE CONVENTIONS? With the events now online, after these next two weeks, both parties will likely sit down and see if in-person conventions need to be changed at all. Do parties need a full week of expensive arena space? Or would that money be better spent on staffing in swing states? Will Americans tune in like they did in 2016 this year? These are just some of the questions that will be asked following the conventions. 2023

The Commission on Presidential Debates announced that they've officially canceled the Oct. 15 debate between President Donald Trump and Democratic presidential nominee Joe Biden.In a press release, the commission stated that since both candidates made different arrangements for Oct. 15, the commission will focus on the third and final presidential debate, which is slated for Oct. 22."Subject to health security considerations, and in accordance with all required testing, masking, social distancing, and other protocols, the debate will take place at Belmont University in Nashville, Tennessee," the commission said in the press release.The move to a virtual debate was as a precaution since Trump tested positive for COVID-19 last week.Trump was airlifted to Walter Reed Medical Center last Friday and then discharged from Walter Reed on Monday.According to the Associated Press, The White House has been mum about releasing any information as to when the president last tested negative for the virus.Trump told Fox Business that he would not "waste his time" with a virtual debate.CNN reported that because of Trump backing out and Biden agreeing to do a town hall with ABC, the commission didn't see the Oct. 15 debate likely happening.NPR reported that another reason behind the cancelation was because the Trump campaign and the commission couldn't agree on safety protocols.The Oct. 22 debate will be divided into six 15-minute segments. NBC News' Kristen Welker, who will be serving as the moderator for the debate, will announce the topics sometime next week.Both candidates have agreed to participate in the Oct. 22 debate, the commission noted. 1665